Piper Jaffray Companies restated their buy rating on shares of Intersect ENT, Inc. (NASDAQ:XENT) in a research report sent to investors on Tuesday. Piper Jaffray Companies currently has a $35.00 target price on the medical equipment provider’s stock.

Several other brokerages have also recently weighed in on XENT. TheStreet upgraded Intersect ENT from a d rating to a c- rating in a research report on Tuesday, August 1st. BidaskClub cut Intersect ENT from a buy rating to a hold rating in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded Intersect ENT from a sell rating to a hold rating in a research report on Wednesday, July 26th. Deutsche Bank AG set a $31.00 price target on Intersect ENT and gave the company a buy rating in a research report on Wednesday, August 2nd. Finally, Canaccord Genuity reiterated a buy rating and issued a $32.00 price target on shares of Intersect ENT in a research report on Wednesday, August 2nd. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $24.88.

Intersect ENT (XENT) opened at 29.55 on Tuesday. Intersect ENT has a 12 month low of $7.65 and a 12 month high of $31.90. The company’s market capitalization is $862.53 million. The company has a 50-day moving average price of $29.20 and a 200 day moving average price of $22.29.

Intersect ENT (NASDAQ:XENT) last issued its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The firm had revenue of $24 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative return on equity of 17.60% and a negative net margin of 22.94%. The business’s revenue was up 24.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.21) earnings per share. On average, equities research analysts forecast that Intersect ENT will post ($0.61) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/26/intersect-ents-xent-buy-rating-reiterated-at-piper-jaffray-companies.html.

In related news, CFO Jeryl L. Hilleman sold 12,835 shares of the business’s stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $27.18, for a total transaction of $348,855.30. Following the completion of the transaction, the chief financial officer now directly owns 27,835 shares in the company, valued at $756,555.30. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Lisa D. Earnhardt sold 20,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $30.79, for a total value of $615,800.00. Following the transaction, the insider now owns 525,868 shares of the company’s stock, valued at $16,191,475.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 98,168 shares of company stock valued at $2,792,537. 13.70% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC boosted its position in Intersect ENT by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 59,774 shares of the medical equipment provider’s stock valued at $723,000 after buying an additional 206 shares during the last quarter. Legal & General Group Plc boosted its position in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. American International Group Inc. boosted its position in Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 1,037 shares during the last quarter. Voya Investment Management LLC boosted its position in Intersect ENT by 9.7% in the second quarter. Voya Investment Management LLC now owns 12,724 shares of the medical equipment provider’s stock valued at $356,000 after buying an additional 1,128 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Intersect ENT by 5.9% in the second quarter. Rhumbline Advisers now owns 29,396 shares of the medical equipment provider’s stock valued at $822,000 after buying an additional 1,625 shares during the last quarter. Institutional investors and hedge funds own 72.78% of the company’s stock.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.